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Abstract
Background Standardized salvage treatment has not yet
proved eVective in glioblastoma multiforme (GBM)
patients who receive prior standard radiotherapy plus con-
comitant and adjuvant temozolomide.
Methods Patients with progressive GBM after radiother-
apy plus concomitant and/or adjuvant temozolomide
received three-weekly doses (100–75 mg m2) of fotemus-
tine followed, after a 5-week rest, by fotemustine
(100 mg m2) every 3 weeks for ·1 year.
Results Forty-three patients (29 M, 14 F; median age
51 years, range 34–68; median KPS 90) were enrolled. Pro-
gression-free survival at 6 months (PFS-6) was 20.9%
(95% CI: 9–33%); three patients (7.1%) had partial
response (PR); 15 (34.9%), disease stabilization (SD). The
median survival was 6 months (95% CI: 5–7). MGMT
promoter status was methylated in 8 (18.6%) and unmethy-
lated in 26 (60.5%) and not assessable in 9 (20.9%)
patients, respectively. Disease control was 75% versus
34.6% in methylated and unmethylated MGMT patients
(P = 0.044); no signiWcant diVerence was found between
groups for PFS-6 and survival. Grade 3 and 4 thrombocyto-
penia and neutropenia were observed in 20.9 and 16.3% of
patients, during the induction phase, and in 0 and 9.5%
patients during the maintenance phase, respectively.
Conclusions The  Wndings of the present trial, that
evaluate fotemustine in a homogeneous population, may
represent a new benchmark for nitrosourea activity. More-
over, this is the Wrst study to evaluate correlation between
MGMT promoter status and outcome of fotemustine for
relapsing GBM previously treated with radiotherapy and
temozolomide.
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Introduction
Worldwide, glioblastoma multiforme (GBM) is the most
frequent primary brain tumor in adults, accounting for 15–
20% of intracranial tumors and 50% of gliomas [6]. The
standard treatment for newly diagnosed GBM with temo-
zolomide (TMZ), concomitant, and adjuvant to radiothera-
py provides a signiWcant increase in overall survival with
respect to radiotherapy alone [27]. However, nearly all
patients treated for GBM faced recurrence. None of the sev-
eral drug regimens reported in literature substantially
delays disease progression [2]. However, promising results
have recently been obtained using novel agents, and new
schedules or synergic combinations [23, 29, 30]. However,
the  Wndings reported following these new approaches
require further conWrmation based on results obtained in
patients who have a longer follow-up.
Nitrosoureas, used alone or in combination with other
agents, are still used as standard second-line chemothera-
py, and are considered the standard arm in randomized
phase II studies for experimental therapy. Moreover, it has
not been demonstrated that nitrosourea-based polychemo-
therapy is anymore eVective against GBM than single
agent chemotherapy. Fotemustine (FTMS), a third genera-
tion chloroethylnitrosourea containing a phosphoalanine
carrier group, is grafted to the nitrosourea radical. Thanks
to the phosphoalanine group contained, the drug is highly
lipophilic; its octanol/water partition coeYcient being
within a range that is more satisfactory than the ranges
obtained with other nitrosoureas, such as carmustine
(BCNU) and lomustine (CCNU). FTMS is able to cross the
blood-brain barrier [16, 18]; in vitro and in vivo studies
have shown that FTMS has a marked anti-neoplastic activ-
ity on human GBM and medulloblastoma cell lines [9, 10].
In their phase I study on 22 GBM patients, Khayat et al.
[14] speciWed the dose of FTMS to be used in clinical prac-
tice: 100 mg m2 for 1-h infusions, conducted on days 1, 8,
and 15 (induction), to be repeated after 4–5 weeks (hema-
tological recovery) every 21 days (maintenance). How-
ever, in the literature, there is little information on activity
and toxicity of this regimen.
The aim of the present phase II study on patients with
recurrent or progressive GBM, who were uniformly treated
with prior radiotherapy and TMZ, was to evaluate the eVect
of FTMS on progression-free survival at 6 months (PFS-6),
response, toxicity and any correlation with O6-methylgua-
nine–DNA methyltransferase (MGMT) gene promoter
methylation status.
Patients and methods
Eligibility
The criteria for eligibility were GBM recurrent or progres-
sive after surgery and TMZ concomitant with and/or adju-
vant to radiotherapy, proven by MRI or CT scans at least
3 months following the radiotherapy end or by two consec-
utive tests. Measurable disease with contrast enhancement
using MRI or CT scans, tested within 2 weeks before study
treatment start. In case of re-surgery before chemotherapy
start, residual measurable disease with contrast enhance-
ment must be proven by MRI or CT scans, performed
within 3 days after surgery. At least one unidimensionally
measurable lesion of ¸2 cm in diameter by MRI. Stable or
decreasing dose of corticosteroids for at least 2 weeks
before patient’s enrollment. At least 4 weeks following
chemotherapy with TMZ. Other inclusion criteria were age
¸18 and ·70 years; Karnofsky performance status ¸60;
adequate bone marrow reserve (absolute neutrophils count
>1.5 £ 109 L¡1; platelets >100 £ 109 L¡1; hemoglobin
>10 g dL¡1); normal renal and liver function (serum creati-
nine <1.25£, upper limit of the normal range (ULN); BUN
< 2 5m gd L ¡1; serum bilirubin ·1.25£ ULN; AST and
ALT · 1.5£ ULN; alkaline phosphatase ·2£ ULN;
remaining life expectancy ¸3 months. Patients with active
infections or other uncontrolled diseases, psychiatric distur-
bances and/or a previous history of cancer (except for
resected non-melanoma skin cancer or carcinoma—in situ
of the uterine cervix), were considered ineligible.
All the histological specimens obtained at Wrst diagnosis
were reviewed by the coordinating center of Azienda
Ospedaliera of Padova (M.G. Department of Pathology) and
the diagnosis of GBM was conWrmed according to the criteria
speciWed in 2007 WHO central nervous tumor classiWcation.
The study, approved by the Institutional Ethics Commit-
tees of all participating centers, was conducted according to
the principles of the declaration of Helsinki and the rules of
good clinical practice.
All patients signed a form giving their fully informed
consent to participate in the study.
Treatment schedule
In line with phase I study protocol and with licensing
instructions of the drug, FTMS 100 mg m2 was adminis-
tered i.v. over 1 h weekly for three consecutive weeks
(induction therapy), followed after 5 weeks by one infusion
of FTMS 100 mg m2 every 3 weeks (maintenance therapy)
for up to 1 year, unless disease progression or unacceptable
toxicity was observed. If, due to toxicity, treatment suspen-
sion was prolonged by more than 2 weeks beyond the next
scheduled cycle of treatment planned, the patient wasCancer Chemother Pharmacol (2009) 64:769–775 771
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permanently withdrawn from the study. Based on the most
severe toxicity experienced since the last cycle, the subse-
quent dose was reduced to 75% in the presence of grade 3
or 4 platelet toxicity, grade 4 neutrophils or white blood
cells or hemoglobin toxicity. In cases of non-hematologic
toxicity, chemotherapy was delayed until recovery to grade
1, for a maximum of 2 weeks (after which the patient was
withdrawn from the study). In cases of recovery to grade 1
after grade 3 or 4 toxicity, a dose of 75% the treatment dose
was administered.
After the inclusion of the Wrst three patients who experi-
enced grade 4 thrombocytopenia following induction ther-
apy, the protocol was amended to reduce FTMS dosage
during induction therapy to 75 mg m2. In fact, this 
life-threatening toxicity was considered unacceptable in the
palliative setting of salvage therapy of GBM patients.
EYcacy measures and toxicity monitoring
Progression-free survival (PFS) was measured as from the ini-
tiation of FTMS to progression or death due to any cause or
last follow-up assessment, whichever comes Wrst. Overall sur-
vival (OS) was measured as from the start of FTMS to death
for any reason, or last follow-up assessment. In this intent to
treat study, data on all registered patients who met the main
inclusion criteria were included in the statistical analysis.
Evaluation of response, conducted in all patients,
included clinical and neurological examinations and MRI
or CT neuro-imaging according to Macdonald’s criteria
[17]. The Wrst evaluation was made after the induction
phase (7 weeks after the Wrst study drug administration);
thereafter evaluations were made every two cycles during
the study treatment (6 weeks) and every 3 months during
the follow-up period, or earlier if indicated. Neurological
status was assessed by considering signs and symptoms
possibly correlated with progression, as compared to the
previous examination; each variation in daily corticoste-
roids dosage was recorded.
Responses were conWrmed as complete (CR), partial
(PR) and stable (SD) if they were constant at subsequent
scans obtained at least 4 weeks apart from each other. An
independent central review of CT and MRI scans was made
for all patients.
All adverse events were recorded and graded according to
the common toxicity criteria of the National Cancer Institute,
version 3.0. (http://ctep.cancer.gov/forms/CTCAEv3.pdf).
DNA extraction and methylation-speciWc 
polymerase chain reaction
MGMT promoter methylation analysis was performed on
tissue taken from the primary surgery specimen before
radiotherapy and TMZ.
DNA from 10 m paraYn sections of cerebral lesion
was modiWed by sodium bisulWte, which converts unmethy-
lated cytosine to uracil, according to the procedure of
Herman et al. [13]. ModiWed DNA was submitted for
methylation-speciWc PCR (MSP) following a nested-PCR
protocol [21]. Since the quality of DNA obtained from for-
malin-Wxed paraYn-embedded tumor tissue aVects the suc-
cess rate of MSP, in some cases MGMT methylation status
was determined by a diVerent nested-MSP approach, with a
Wrst pair of primers to obtain smaller amplicons (129 bp),
for which forward and reverse primers have been described
[21, 28].
End points and statistical analysis
Data from all patients, who received at least one drug
delivery and for whom at least one tumoral evaluation was
performed, were included in the response analysis.
The primary eYcacy endpoint of the study was the
percentage of patients free from disease progression at
6 months (PFS-6). Drug activity was evaluated following a
one-stage Fleming study design for determination of
response rates based on a single-treatment group. A sample
size of 40 patients was estimated using exact binomial
method and assuming: one-tailed  equal to 0.1, (1-) equal
to 0.9 and <0.1 (null hypothesis) versus  ¸ 0.25 (alterna-
tive hypothesis), where  was the observed 6-month disease
progression-free probability. If seven or more patients were
evaluated as PFS-6, it was assumed that the drug was
active.
Secondary objectives were the rate of best observed
response, deWned as the best response during the treatment
and evaluated with Macdonald’s criteria [17]; duration of
objective response and stabilization; duration of complete
response; time to disease progression, overall survival, tox-
icity, and evaluation of MGMT methylation and the correla-
tion with clinical outcome. All patients receiving the study
drug were included in the safety analysis. Median time to
progression (mTTP) and median survival were also esti-
mated with associated 95% CI. PFS-6 and OS were calcu-
lated using the Kaplan–Meier method; diVerences in PFS-6
and OS were compared using the log rank test for statistical
signiWcance.
Results
Patients’ characteristics
From April 2005 to May 2006, 43 patients (29 males;
median age: 51 years, range: 34–68 years; median: KPS 90)
were enrolled in the study. The demographic and clinical
characteristics of patients are outlined in Table 1. Each772 Cancer Chemother Pharmacol (2009) 64:769–775
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patient had completed external-beam radiation therapy
(60 Gy/30 F) concurrent and/or followed by adjuvant TMZ.
Median number of TMZ cycles was 5 (range 1–23). No
patient underwent a second surgical procedure at the time
of progression following TMZ administration. Median time
between TMZ treatment completion and FTMS start was
1.5 months (range 1–43). Thirty patients (69.8%) started
FTMS within 3 months from TMZ last administration. At
time of FTMS initiation 26 patients (60.5%) were on
enzyme-inducing antiepileptic drugs (EIAEDs), while 11
patients (25.6%) were on non-EIAEDs and 6 patients
(13.9%) were not on antiepileptic drugs. The median dura-
tion of follow-up was 7.4 months (range 1.2–22.7). In 39 of
the 43 patients enrolled in the trial, enough histological
material was obtained for evaluation of MSP. MSP was
assessable on 34 of these 39 patients. MGMT promoter
status was methylated in 8 (18.6%) and unmethylated in
26 (60.5%) and not assessable in 9 (20.9%) patients,
respectively.
Progression-free survival
Nine patients (20.9%; 95% CI: 9–33%) were PFS-6 and the
median PFS was 1.7 months.
The percentages of PFS-6 with MGMT promoter methyl-
ated or unmethylated status were 25% (95% CI: 7.5–83%)
and 19.2% (95% CI: 8.7–42.3%), respectively. PFS-6 in the
population (n = 40) treated after the amendment was
22.5%, not signiWcantly diVerent with the entire population
of 43 pts.
No signiWcant diVerences were found between median
PFS, evaluated using the log rank test, in relation to age
(P = 0.89), KPS (P =0 . 3 3 ) ,  a n d  MGMT promoter methyl-
ated or unmethylated status (P = 0.15). No signiWcant inXu-
ence of type of antiepileptic drug was seen, being PFS-6
26.9% and 11.7% in patients on EIAEDS and on non-
EIAEDS plus not on antiepileptic drugs, respectively
(P =0 . 2 8 ) .
Patients that initiated FMTS at least 3 months after TMZ
completion showed a signiWcantly higher PFS-6, (30.7 vs.
16.7%) than patients who initiated FTMS immediately after
TMZ completion (P =0 . 0 3 4 ) .
Response
Among the 43 assessable patients, 3 had partial responses
(7.1%, 95% CI: 0–15%), and 15 stable disease (34.9%,
95% CI: 21–49%). Disease control rate (SD+PR) in the
population treated after the amendment was 42.5%, not sig-
niWcantly diVerent with the entire population. All responses
were conWrmed by an independent centralized review, and
stable or decreased steroid dosage was conWrmed in all
patients at the time of recording response. Median duration
of response was 9.1 months (95% CI: 1.7–16.4), and
median duration of disease stabilization was 5 months
(95% CI: 1.2–8.9). Disease control rate was signiWcantly
greater in methylated and unmethylated MGMT patients, 75
and 34.6% (P = 0.044), respectively; and in patients who
started FTMS at least 3 months after TMZ administration
had been concluded (76.9 vs. 26.7%, P =0 . 0 0 2 ) .
No signiWcant inXuence of type of antiepileptic drug was
seen, being disease control rate 42.3 and 41.2% in patients
on EIAEDS and on non-EIAEDS plus non on antiepileptic
drugs, respectively (P =0 . 9 8 ) .
Overall survival
The median overall survival was 6 months (95% CI: 5–7).
The median overall survival of the population treated after
the amendment was 6 months. No statistical diVerence has
been found between patients with methylated and those
with unmethylated MGMT promoter status: being 6 months
(95% CI: 0–14.2) versus 5.5 months (95% CI: 4.2–6.8).
The median overall survival for patients who started
FTMS at least 3 months after TMZ administration had been
concluded was 8.4 months (95% CI: 2.6–14) versus
5.4 months (95% CI: 4.2–6.5) for patients who initiated
FTMS immediately after TMZ completion (P =0 . 0 2 2 ) .
The percentage of patients alive at 6 months was 51%
(95% CI: 38–68%), without diVerence between patients
with methylated or unmethylated MGMT promoter status
Table 1 Patients’ characteristics
Number of patients %
Sex
Male 29 67
Female 14 33
Age
Median years (range) 51 (34–68)
Karnofsky performance status (KPS)
Median (range) 90 (70–100)
Extent of resection
Macroscopically radical 28 65
Partial 12 28
Biopsy 3 7
Radiotherapy/TMZ 43 100
MGMT status
Methylated 8 18.6
Unmethylated 26 60.5
Unknown 9 20.9
FTMS initiation and time to TMZ treatment completion
Within 3 months 30 69.8
Beyond 3 months 13 30.2Cancer Chemother Pharmacol (2009) 64:769–775 773
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62.5% (95% CI: 36.5–100%) versus 46% (95% CI: 30.5–
70%). Only disease control rate obtained with FTMS was
signiWcantly correlated with survival (P =0 . 0 0 2 ) .
Treatment and toxicity
All 43 patients completed the induction phase as planned.
After induction phase grade 3–4 thrombocytopenia and
neutropenia were documented in 9 (20.9%) and 7 out 43
patients (16.3%), respectively; grade 3–4 lymphopenia was
found in four patients (9.3%). The study was emended after
the Wrst three patients by decreasing the FTMS induction
dose from 100 mg m2 once a week for 3 weeks to
75 mg m2. Of note, the Wrst three patients that received
induction therapy at the dosage of 100 mg m2 aged 48, 51,
and 62 years, had a KPS of 100, 100, and 80, started FTMS
30, 40, and 95 days after TMZ completion, respectively,
and did not have signiWcant comorbidities to justify
increased toxicities.
The grade 3–4 thrombocytopenia reported for the induc-
tion phase in the 40 patients treated after this amendment
was 15%.
Twenty-one (49%) patients started maintenance chemo-
therapy and received a median of two cycles (range 1–14).
The main reason for not beginning maintenance therapy
after the induction part was disease progression. Only one
patient, with prolonged grade 2 neutropenia, discontinued
therapy due to toxicity after the induction phase. The toxic-
ity of the maintenance phase was grade 3 leukopenia and
grade 4 neutropenia in 14 and 9.5% of the patients, respec-
tively; no patient experienced grade 3–4 thrombocytopenia
(Table 2). The most commonly reported grade 3–4 non-
hematological toxicity were nausea and vomiting in two
(4.6%) patients and transaminase elevation in four patients
(9.3%). Pneumonia was reported in one patient (2.3%).
Discussion
TMZ concomitant and adjuvant to radiotherapy, which has
become the standard treatment for newly diagnosed GBM
patients, prolongs overall and progression-free survival
more eVectively than radiotherapy alone [27]. Conse-
quently, Wrst-line chemotherapy has become more homoge-
neous than it was in the past. However, while the outcome
of patients with newly diagnosed GBM has improved
worldwide, recurrence continues to be virtually inevitable.
The choice of second-line chemotherapy is therefore of
utmost importance in the large number of patients who con-
tinue to have a satisfactory PS and are willing to receive
further treatment, nitrosourea being the most widely used
therapeutic option. However, the real impact of this salvage
chemotherapy in terms of activity, disease control, and
toxicity after TMZ failure is still largely unknown. The
present study is the Wrst trial to evaluate correlation
between MGMT methylation status (assessable in 79% of
patients) and outcome of nitrosourea-based chemotherapy
for progressing/relapsing glioblastoma previously treated
with radiotherapy and TMZ in the adjuvant setting. Data on
the outcome of fotemustine administration, used as second-
line treatment in GBM patients were reported by Scoccianti
et al. [26], and Fabrini et al.[8]; the authors reported a simi-
lar PFS-6 rates (48 and 52%, respectively), disease control
rate (48 and 62%, respectively), grade 3–4 hematological
toxicities (14.8 and 10%, respectively).
The results from these series seem to be better than ours
both in terms of outcome and of toxicity. However, com-
parison across trials is always challenging. Moreover, the
lack of MGMT methylation status data in the other FTMS
studies and the small number of patients included in these
three studies might justify the diVerences, and highlight the
relevance of performing larger prospective trials in this
patient population.
We decided to modify the fotemustine dose recom-
mended in a prior phase I trial [14] and in other studies on
glioma or melanoma patients [1, 15, 19, 20, 25], as grade 4
thrombocytopenia was observed after induction therapy in
the Wrst three patients and this life-threatening toxicity was
considered unacceptable in the palliative setting of salvage
therapy of GBM patients. This is consistent with the previ-
ous observation that hematological toxicity is increased by
prior chemotherapy [24]. Moreover, the following 40
patients, treated with the reduced dosage of FTMS during
induction phase, experienced a 15% of grade 3–4 thrombo-
cytopenia and neutropenia.
Table 2 Hematological toxicities during and after induction and
during the maintenance phase
Adverse 
Event
Induction 
(n =4 3 )  
[% (Pts/Total)]
Induction after 
amendment 
(n = 40) 
[% (Pts/Total)]
Maintenance 
(n = 21) 
[% (Pts/Total)]
Thrombocytopenia
Grade 3 11.6 (5/43) 12.5 (5/40) 0.0 (0/21)
Grade 4 9.3 (4/43) 2.5 (1/40) 0.0 (0/21)
Leukopenia
Grade 3 7.0 (3/43) 5.0 (2/40) 14.3 (3/21)
Grade 4 2.3 (1/43) 2.5 (1/40) 0.0 (0/21)
Neutropenia
Grade 3 9.3 (4/43) 10.0 (4/40) 0.0 (0/21)
Grade 4 7.0 (3/43) 5.0 (2/40) 9.5 (2/21)
Lymphopenia
Grade 3 7.0 (3/43) 7.5 (3/40) 14.3 (3/21)
Grade 4 2.3 (1/43) 2.5 (1/40) 0.0 (0/21)774 Cancer Chemother Pharmacol (2009) 64:769–775
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Maintenance fotemustine showed hematological toxici-
ties similar to those showed by BCNU delivered at Wrst-
relapse (grade 3–4 neutropenia and thrombocytopenia in 10
and 8% of patients, respectively) [3]. However, no cumula-
tive dose limit for fotemustine was found by us, whereas
the use of BCNU is complicated by pulmonary toxicity (G4
toxicities occurring in 5% of cases [3]), which severely
compromises quality of life, and life expectancy and leads
to discontinuation of therapy (10%).
Fotemustine administration was found to be more feasi-
ble and tolerable than PCV treatment, incurring fewer cases
of discontinuation due to toxicity (2.3 vs. 43%) [5]. In
terms of disease control, fotemustine yielded a PFS-6 of
21%, which met the primary eYcacy end point of the study
by conWrming the drug activity.
Apparently promising results (response rate, 57%; PFS-
6, 46%; 6-month overall survival, 77%) were recently
reported following the use of combined irinotecan and bev-
acizumab [29]. However, these drugs have not yet been
registered by FDA or EMEA and nor are they available
worldwide, nitrosoureas continuing to be the most com-
monly used second-line standard therapy.
Other interesting approaches include TMZ re-challenge,
which was recently investigated by Perry et al. In their
retrospective analysis, the authors showed that TMZ
re-challenge with a continuous 50 mg m¡2 daily schedule is
an intriguing approach, especially for patients with recur-
rence after completion of TMZ administration concurrent
with and adjuvant to radiotherapy: GBM patients failing
during the Wrst 3–6 months of adjuvant therapy (B1); GBM
patients failing after more than 6 months of therapy (B2);
GBM patients who recurred after stopping treatment (B3).
PFS-6 rates were 28.6% (B1), 9.5% (B2), 30.4% (B3) [22].
Our Wndings are in line with these observations: patients in
our series who initiated FMTS at least 3 months after com-
pletion of TMZ administration had a signiWcantly higher
PFS-6, (30.7 vs. 16.7%) than patients who initiated FTMS
while still on TMZ, P = 0.034).
MGMT promoter methylation was found to be an inde-
pendent favorable prognostic factor, irrespective of treat-
ment, in newly diagnosed GBM patients [12]. Conversely,
little information is available on the trend of MGMT
expression during tumoral progression, and after diVerent
chemotherapeutic treatments. In the present study, an anal-
ysis was made of the correlation between clinical outcome
after fotemustine and MGMT promoter methylation status;
to our knowledge, ours is the Wrst study to analyze the cor-
relation between MGMT promoter methylation status and
second-line treatment. Adequate paraYn embedded tumor
tissue was available in a higher percentage of patients than
in other MSP studies (79 vs. 59–67%) [11, 12]. The per-
centage of methylated patients found in our study was
clearly smaller than those reported in other series given
upfront and/or salvage therapy (24 vs. 40–47%) [7, 12].
Moreover, we found that disease control rate was 75
and 34.6% in methylated and unmethylated patients
(P = 0.044). On the other hand, no signiWcant diVerence
was found between groups for PFS-6 and survival; this
Wnding, which is in line with that reported in other series of
heterogeneously pre-treated patients who underwent
salvage therapy [4], may reXect or a diVerent pattern of
resistance at progression, or a change in MGMT status
at progression. A trend toward prolonged PFS-6 was
observed, the lack statistical signiWcance probably
reXecting limited statistical power due to the relatively
small number of cases in the present study, which pre-
cluded the demonstration of this secondary endpoint. It is
important to bear in mind that MGMT methylation analysis
was not made in trials that reported more favorable results
[29]. For a reliable assessment of the role of this variable at
the time of salvage, a prospective report should be under-
taken to evaluate MGMT methylation status and, hopefully,
to stratify patients enrolled in second-line treatment future
trials. The Wndings made in the present trial may thus
represent a new benchmark of nitrosourea activity in a
homogeneously   pre-treated population that failed to respond
to the new standard treatment.
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